MX2021002611A - Composición farmacéutica que comprende complejos de ciclodextrina de anetol tritiona o derivados del mismo. - Google Patents

Composición farmacéutica que comprende complejos de ciclodextrina de anetol tritiona o derivados del mismo.

Info

Publication number
MX2021002611A
MX2021002611A MX2021002611A MX2021002611A MX2021002611A MX 2021002611 A MX2021002611 A MX 2021002611A MX 2021002611 A MX2021002611 A MX 2021002611A MX 2021002611 A MX2021002611 A MX 2021002611A MX 2021002611 A MX2021002611 A MX 2021002611A
Authority
MX
Mexico
Prior art keywords
cyclodextrin
compexes
derivatives
pharmaceutical composition
formula
Prior art date
Application number
MX2021002611A
Other languages
English (en)
Inventor
Nicolas Pineau
El Mustapha Belgsir
Frédéric Turpin
Anne Gaëlle FOURNIAL
Aswin Dereymaker
Natascha Audoore
Cock Ine De
Original Assignee
OP2 Drugs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by OP2 Drugs filed Critical OP2 Drugs
Publication of MX2021002611A publication Critical patent/MX2021002611A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/16—Cyclodextrin; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a una composición que comprende anetol tritiona o un derivado del mismo de la Fórmula (I), sulfobutil éter-betaciclodextrina y opcionalmente un co-solvente, en donde la relación entre sulfobutil éter-beta-ciclodextrina y el compuesto de la Fórmula (I) varía de 10 a 400, preferentemente de 57 a 200. La invención se refiere además a la composición descrita en la presente solicitud para su uso como un fármaco, es decir, para el tratamiento y/o la prevención de enfermedades relacionadas con radicales de oxígeno libres. La invención también se dirige a un equipo de partes y/o a un dispositivo médico que comprende dicha composición. Por último, la presente invención se refiere a un método para solubilizar un compuesto de la Fórmula (I) en un medio acuoso.
MX2021002611A 2018-09-06 2019-09-06 Composición farmacéutica que comprende complejos de ciclodextrina de anetol tritiona o derivados del mismo. MX2021002611A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862727691P 2018-09-06 2018-09-06
EP18306172 2018-09-06
PCT/EP2019/073873 WO2020049166A1 (en) 2018-09-06 2019-09-06 Pharmaceutical composition comprising cyclodextrin compexes of anethole trithione or derivatives thereof

Publications (1)

Publication Number Publication Date
MX2021002611A true MX2021002611A (es) 2021-07-21

Family

ID=67841092

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021002611A MX2021002611A (es) 2018-09-06 2019-09-06 Composición farmacéutica que comprende complejos de ciclodextrina de anetol tritiona o derivados del mismo.

Country Status (11)

Country Link
US (1) US20210308173A1 (es)
EP (1) EP3846856A1 (es)
JP (1) JP7362725B2 (es)
KR (1) KR20210054540A (es)
CN (1) CN113038969A (es)
AU (1) AU2019336943A1 (es)
BR (1) BR112021003997A2 (es)
CA (1) CA3111886A1 (es)
IL (1) IL281161B2 (es)
MX (1) MX2021002611A (es)
WO (1) WO2020049166A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023554184A (ja) * 2020-12-10 2023-12-26 マリン，フレデリク 虚血再灌流傷害の予防又は治療のためのアネトールトリチオン投与治療計画
EP4112051A1 (en) 2021-06-30 2023-01-04 Op2 Drugs Anethole trithione for the treatment of vasculitides
CN114558004B (zh) * 2022-03-29 2023-08-11 奎马特里克斯有限公司 Qtx125药物制剂
CN115738757B (zh) * 2022-11-24 2024-03-29 中国海洋大学 一种基于磺丁基-β-环糊精离子传输通道的单价阳离子选择性分离膜及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262165A (en) 1992-02-04 1993-11-16 Schering Corporation Transdermal nitroglycerin patch with penetration enhancers
US6010715A (en) 1992-04-01 2000-01-04 Bertek, Inc. Transdermal patch incorporating a polymer film incorporated with an active agent
UA48973C2 (uk) 1995-06-07 2002-09-16 Орто-Макнейл Фармасьютікалз Інк. Трансдермальний пластир на основі 17-деацетилноргестимату для попередження овуляції
AU5474198A (en) * 1996-12-24 1998-07-17 National Research Council Of Canada Treatment of diseases or prevention of cellular damage caused by oxygen-containing free radicals
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
CN1771938A (zh) 2004-11-09 2006-05-17 胡才忠 茴三硫脂质体及其制备方法
BR112018004518A2 (pt) * 2015-09-08 2019-03-19 OP2 Drugs compostos para o tratamento de doenças ligadas à produção de espécies reativas de oxigênio (ros) mitocondriais
KR20180049019A (ko) 2015-09-08 2018-05-10 오피2 드러그스 미토콘드리아의 반응성 산소 종 (ros) 생성과 관련된 질환 치료용 화합물
AU2018232799B2 (en) * 2017-03-07 2021-11-25 Centre Hospitalier Universitaire De Bordeaux Desmethylanethole trithione derivatives for the treatment of diseases linked to mitochondrial reactive oxygen species (ROS) production

Also Published As

Publication number Publication date
IL281161B1 (en) 2023-09-01
EP3846856A1 (en) 2021-07-14
WO2020049166A1 (en) 2020-03-12
CN113038969A (zh) 2021-06-25
JP2021536472A (ja) 2021-12-27
US20210308173A1 (en) 2021-10-07
KR20210054540A (ko) 2021-05-13
JP7362725B2 (ja) 2023-10-17
IL281161B2 (en) 2024-01-01
CA3111886A1 (en) 2020-03-12
BR112021003997A2 (pt) 2021-05-25
IL281161A (en) 2021-04-29
AU2019336943A1 (en) 2021-03-18

Similar Documents

Publication Publication Date Title
MX2021002611A (es) Composición farmacéutica que comprende complejos de ciclodextrina de anetol tritiona o derivados del mismo.
MX2021007970A (es) Derivado de 6-oxo-1,6-dihidropiridazina, metodo de preparacion del mismo y uso medico del mismo.
MX2022015260A (es) 2-amino-3-cianotiofenos anulados y derivados para el tratamiento del cancer.
MX2021003655A (es) Derivado de indol macrociclico, metodo de preparacion del mismo y aplicacion del mismo en medicina.
MX2022015272A (es) Inhibidores de la proteina kras g12c y usos de estos.
CY1119488T1 (el) Παραγων για θεραπεια ή/και αποτροπη διαταραχης υπνου
CY1115289T1 (el) Μεθοδοι αγωγης εναντι ασθενειας που σχετιζεται με φλεγμονη
BR112015011497A2 (pt) composto, formulação farmacêutica, produto de combinação, e, método de tratamento de uma doença
CY1122792T1 (el) Παραγωγα μονο- ή δισυποκατεστημενης ινδολης ως αναστολεις αναδιπλασιασμου δαγκειου ιου
EA201992784A1 (ru) Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
PH12019502201A1 (en) Substituted indoline derivatives as dengue viral replication inhibitors
BRPI0507198A (pt) derivados de bisariluréia
MY195194A (en) Substituted Indoline Derivatives as Dengue Viral Replication Inhibitors
BR0209027A (pt) Composto ácido carboxìlico e seu uso, medicamento, agente e método para a prevenção ou tratamento de uma doença, composição farmacêutica
EA201992782A1 (ru) Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
MX2023000314A (es) Formulaciones farmaceuticas transdermicas de cannabinoides.
EA202192900A1 (ru) Модуляторы пути интегрированной реакции на стресс
NZ748771A (en) Pharmaceutical compositions comprising nitroxyl donors
BR112019018615A2 (pt) compostos antimicrobianos, composições e usos dos mesmos
WO2018183631A8 (en) Novel pharmaceutical formulations containing indirubin and derivatives thereof and methods of making and using the same
MX2024001777A (es) Derivado de sulfonamida, metodo de preparacion y uso medico del mismo.
MX2024004921A (es) Derivados de piperidinilindol, metodos de preparacion y usos medicinales de estos.
MX2021006724A (es) Compuestos de halo-alilamina y uso de los mismos.
MX2021009539A (es) Derivado del profarmaco 6-oxo-1,6-dihidropiridazina, metodo de preparacion del mismo y aplicacion del mismo en medicina.
PH12020550775A1 (en) Pentosan polysulfate and medicine containing pentosan polysulfate